Ardelyx, Inc.
$5.03 -$0.10 (-1.95%) 1D After hours
Ardelyx, Inc.
Key Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 24
From its Jan 29 high, the share price fell 36%.
Peak close $7.85 on Jan 29; trough close $5.03 on Jul 24. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -36% -
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Feb 24
The stock moved +14.1% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Feb 24 -
Feb 20
The stock moved -15.0% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Feb 20
The story updates itself as events post · The wolf reports; you decide
Snapshot
About Ardelyx, Inc.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.